Lead by Marcela Maus, MD, PhD and Matthew Frigault, MD, the Cellular Immunotherapy Program brings together physicians and laboratory scientists focused on immune cell engineering and its clinical effects.
Marcela Maus, MD, PhD
Director, Cellular Immunotherapy Program
Mass General Cancer Center
Marcela Maus, MD, PhD
Director, Cellular Immunotherapy Program
Paula O’Keeffe Chair in Oncology
Attending Physician
Hematopoietic Cell Transplant & Cell Therapy Program
Massachusetts General Hospital
Associate Member, Broad Institute of MIT and Harvard
Professor of Medicine, Harvard Medical School
Associate Head & Head of Cell Therapies, Gene and Cell Therapy Institute, Mass General Brigham
Dr. Maus is the Paula O'Keeffe Endowed Chair of the Massachusetts General Hospital Cancer Center and the Director of the Cellular Immunotherapy Program. She is also a Professor of Hematology and Oncology at Massachusetts General Hospital and Harvard Medical School, where she runs a laboratory focused on developing and improving CAR T cell therapy for cancer patients while also periodically attending for the bone marrow transplant service. Dr. Maus grew up in New York, NY and attended Massachusetts Institute of Technology for her undergraduate degree in Biology and Literature. She then earned her MD, PhD from the University of Pennsylvania School of Medicine under the direction of her PhD mentor, Dr. Carl June. She then did a one-year postdoctoral fellowship with Dr. Kathy High at the Children’s Hospital of Philadelphia, completed her clinical training in internal medicine, hematology, and oncology as a resident at the University of Pennsylvania Health System, and was a fellow at Memorial Sloan Kettering Cancer Center in Dr. Michel Sadelain’s lab.
Following her extensive training, Marcela returned to the University of Pennsylvania in 2012 to expand research efforts in the development of CAR T cells for lymphoma, myeloma, and other cancers. While there, Marcela continued her efforts on the preclinical development of CAR T cells and correlative studies of CAR T cell-related toxicities and resistance to therapies. Now, Dr. Maus runs a laboratory focused on developing and improving CAR T cell therapy for cancer patients. She has won numerous awards for her transformative research and is achieving her goal of using science to determine the best way to treat patients by harnessing the power of the immune system to solve intractable problems like cancer. She also enjoys training clinicians and scientists and watching her mentees succeed and become independent scientists and collaborators. Marcela is also a mother to three children, one large dog and one gecko. In her free time, Marcela enjoys spending time with her husband, kids, and pets, gardening, and skiing.
Matthew Frigault, MD
Administrative Director, Cellular Therapy Service
John and Ashley Ranelli Endowed Scholar in Cancer Innovation
Mass General Cancer Center
To bring therapies to patients, a dedicated team of early-phase clinical investigators in oncology play a central role in cancer immunology at Mass General.
Jeremy Slade Abramson, MD
Director, Jon and Jo Ann Hagler Center for Lymphoma
Mass General Cancer Center
Patricia Brunker, MD, DPhil
Director, Blood Transfusion Center
Mass General Hospital
Yi-Bin Chen, MD
Director, Hematopoietic Cell Transplant & Cell Therapy Program
Mass General Cancer Center
Edwin Choy, MD, PhD
Director, Center for Sarcoma and Connective Tissue Oncology
Mass General Cancer Center
William Curry, MD
Director, Neurosurgical Oncology
Mass General Hospital
Amir Fathi, MD
Director, Center for Leukemia
Mass General Cancer Center
Matthew Frigault, MD
Administrative Director, Cellular Therapy Service
John and Ashley Ranelli Endowed Scholar in Cancer Innovation
Mass General Cancer Center
Justin F. Gainor, MD
Director, Center for Thoracic Cancers
Mass General Cancer Center
Tim Graubert, MD
Director, Hematologic Malignancy Program
Mass General Cancer Center
Donald Lawrence, MD
Clinical Director, Center for Melanoma
Mass General Cancer Center
Marcela Maus, MD, PhD
Director, Cellular Immunotherapy Program
Mass General Cancer Center
Noopur Suresh Raje, MD
Director, Center for Multiple Myeloma
Mass General Cancer Center
Ryan J. Sullivan, MD
Director, Center for Melanoma
Mass General Cancer Center
Lori Wirth, MD
Medical Director, Center for Head and Neck Cancers
Mass General Cancer Center
Magdi Elsallab, MD, PhD
Director, Process Development Lab
Lab Director, Cellular Therapy and Transplantation Laboratory
Mass General Cancer Center
Kathleen Gallagher, PhD
Director, Immune Monitoring Laboratory
Mass General Cancer Center
Thomas Spitzer, MD
Medical Director, Cellular Therapy and Transplantation Laboratory
Mass General Cancer Center
Inas Abuali, MBCHB
Mass General Cancer Center
Philip Amrein, MD
Center for Leukemia
Mass General Cancer Center
Andrew Branagan, MD, PhD
Center for Multiple Myeloma
Mass General Cancer Center
Bryan Choi, MD, PhD
Department of Neurosurgery
Mass General Hospital
Diana Cirstea, MD
Center for Multiple Myeloma
Mass General Cancer Center
Gregory Cote, MD, PhD
Center for Sarcoma and Connective Tissue Oncology
Mass General Cancer Center
Elijah Darnell, MD
Fellow
Mass General Cancer Center
Zachariah DeFilipp, MD
Bone Marrow Transplant Program
Mass General Cancer Center
Tejaswini More Dhawale, MD
Mass General Cancer Center
Jorg Dietrich, MD, PhD
Pappas Center for Neuro-Oncology
Mass General Cancer Center
Areej El-Jawahri, MD
Bone Marrow Transplant Program
Mass General Cancer Center
Xin Gao, MD
Claire and John Bertucci Center for Genitourinary Cancers
Mass General Cancer Center
Elizabeth Gerstner, MD
Pappas Center for Neuro-Oncology
Mass General Cancer Center
Alexandra Haugh, MD, MPH
Center for Melanoma
Mass General Cancer Center
Erika Haydu, MD, PhD
Jon and Jo Ann Hagler Center for Lymphoma
Mass General Cancer Center
Salvia Jain, MD
Jon and Jo Ann Hagler Center for Lymphoma
Mass General Cancer Center
Patrick Connor Johnson, MD
Jon and Jo Ann Hagler Center for Lymphoma
Mass General Cancer Center
Michael Lanuti, MD
Division of Thoracic Surgery
Mass General Hospital
Mark Leick, MD
Bone Marrow Transplant Program
Mass General Cancer Center
Steven McAfee, MD
Clinical Director, Bone Marrow Transplant Program
Mass General Cancer Center
Rupa Narayan, MD
Center for Leukemia
Mass General Cancer Center
Richard Newcomb, MD
Bone Marrow Transplant Program
Mass General Cancer Center
Paul O'Donnell, MD, PhD
Mass General Cancer Center
Chirayu Patel, MD, MPH
Department of Radiation Oncology
Mass General Cancer Center
Benjamin Puliafito, MD
Center for Multiple Myeloma
Mass General Cancer Center
Meghan Sise, MD
Division of Nephrology
Mass General Hospital
Jacob Soumerai, MD
Jon and Jo Ann Hagler Center for Lymphoma
Mass General Cancer Center
Oladapo Yeku, MD, PhD, FACP
Center for Gynecologic Oncology
Mass General Cancer Center
The Immune Monitoring Laboratory is an essential and integral part of the Cellular Immunotherapy Program. The laboratory provides expertise to enable translational clinical studies of immune-based therapies, based on the highest standard operating systems.
Kathleen Gallagher, PhD
Director, Immune Monitoring Laboratory
Mass General Cancer Center
Magdi Elsallab, MD, PhD
Director, Process Development Lab
Lab Director, Cellular Therapy and Transplantation Laboratory
Mass General Cancer Center
The Blood Transfusion Service is an FDA-licensed, full-service blood bank that consists of the Blood Donor Center, the Outpatient Infusion Unit, the Apheresis Unit, the Transfusion Service, and the Histocompatibility (HLA) Laboratory.
Patricia Brunker, MD, DPhil
Director, Blood Transfusion Center
Mass General Hospital
The Cellular Therapeutics and Transplantation Laboratory team plays an integral part in stem cell processing, transplant infusions and bone marrow harvests at Mass General Cancer Center.
Magdi Elsallab, MD, PhD
Director, Process Development Lab
Lab Director, Cellular Therapy and Transplantation Laboratory
Mass General Cancer Center
Thomas Spitzer, MD
Medical Director, Cellular Therapy and Transplantation Laboratory
Mass General Cancer Center
The Cellular Immunotherapy Program is working to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects.
